We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Robyn
Heath
robyn.heath@bristol.ac.uk
Calum
Masterton
calum.masterton@nihr.ac.uk
Tom
May
t.may@bristol.ac.uk
Rachel
Todd
rachel.todd@bristol.ac.uk
Tom
May
t.may@bristol.ac.uk
Rachel
Todd
rachel.todd@bristol.ac.uk
Tom
May
t.may@bristol.ac.uk
Human immunodeficiency virus [HIV] diseaseViral hepatitis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
In November 2021,funding was allocated to ensure that some emergency departments (ED) implement opt-out testing for HIV in locations with very high prevalence. This initiative was expanded to include opt-out testing for hepatitis B (HBV) and hepatitis C (HCV) to align with global targets for eliminating these diseases.
As part of an opt-out strategy,an ED attendee is not required to agree to a test,but instead informed by clear and simple messaging displayed in EDs (including posters) that a test will be performed unless it is specifically declined. EDs are good places for testing because they can reach people who are less likely to attend a sexual health clinic for testing,or those who might be disproportionally affected by higher rates of HIV/HBV/HCV,such as migrants.
Whilst some studies have shown that opt-out ED testing can be useful in finding new cases of HIV/HBV/HCV,there are still issues to figure out,like why some people don't follow up with care even after being diagnosed,and why testing rates in some EDs are not as high as they should be. This study wants to investigate these problems and find ways to improve the delivery of opt-out testing in EDs.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
BBV opt-out testing All patients attending ED and requiring blood work will be included if they do not opt out of testing. Qualitative research - exclusion criteria Only those included in the qualitative research study will be recruited. Participants/patients will be excluded if they meet any of the following criteria: ED Staff • A member of ED staff not involved in the implementation of ED BBV testing. • Unable to provide informed consent or understand the study information provided. • Not living in UK. • No involvement in implementation and delivery of ED opt-out testing in emergency departments. ED patients • Under 18 years of age. • Unable to provide informed consent or understand the study information provided. • Not living in UK. • Not offered offered a BBV testing as part of a routine blood test in an ED within participating sites.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Tom
May
t.may@bristol.ac.uk
Calum
Masterton
calum.masterton@nihr.ac.uk
Rachel
Todd
rachel.todd@bristol.ac.uk
Rachel
Todd
rachel.todd@bristol.ac.uk
Tom
May
t.may@bristol.ac.uk
Robyn
Heath
robyn.heath@bristol.ac.uk
Tom
May
t.may@bristol.ac.uk
The study is sponsored by University of Bristol and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 58197
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
